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Objectives
After completion of this program, the reader should be able to:
1. List the signs of depression in pregnancy.
2. Outline appropriate pharmacologic and nonpharmacologic treatment regimens for pregnant women who
are diagnosed with depression as well as for women
with postpartum depression during breastfeeding.
3. State the pharmacist’s role in the management of depression in women who are pregnant and those experiencing postpartum depression.
4. Explain when antidepressants start to relieve symptoms and how long they take to reach their full effect.
5. Explain the role of exercise physiology in managing
depression during pregnancy.
Abstract
Depression during pregnancy is common, whether it is a
new onset of the disease or emerging symptoms of the
already existent disease. Due to patient and prescriber concerns with antidepressant use during pregnancy, approximately three-quarters of those diagnosed with depression
remain untreated. Furthermore, up to half of pregnant
women with depression remain undiagnosed due to lack of
recognition. As a result, both mother and fetus are at risk for
negative health outcomes including substance abuse, functional impairment, increased risk of postnatal depression
and poor pregnancy outcomes. Benefits must be balanced
against the risks when considering pharmacologic treatment
options to manage depression during pregnancy. Health care
professionals must also consider the secondary effects of
unmanaged depression during pregnancy such as the physical health of the patient. Nonpharmacologic options such as a
balanced physical activity regimen and nutritional health
may be considered to help improve the well-being of the patient. Therefore, it is important for health care professionals
to be educated on the treatment and management of depression in pregnancy to help patients achieve optimal outcomes
not only for maternal mental and physical health but also for
the health of the fetus.

2

Key Terms
Antidepressive Agents; Depression; Postpartum Period;
Depressive Disorder; Exercise; Female; Fetus; Mothers;
Pregnancy; Pregnancy Outcome
Introduction
Depression can occur in pregnancy both as new-onset disease and as an exacerbation of existing disease. While the
pathophysiology of depression remains unclear, it affects
about 20 percent of women during pregnancy and has negative effects on pregnancy outcomes such as birth weight of
the infant and preterm delivery.1 Antidepressant therapy
while pregnant or breastfeeding is controversial as many of
the drugs commonly used in depression have a lack of evidence for use during pregnancy and breastfeeding. This results in both provider and patient reluctance to initiate new
drug therapy during pregnancy or while breastfeeding. However, there are other, nonpharmacologic methods of treating
depression including interpersonal therapy (IPT), psychotherapy, acupuncture and exercise. A risk-versus-benefit
analysis should always be conducted when determining
which therapy is appropriate for a given patient. It is also
important to consider the risks of untreated depression during pregnancy including postpartum depression, decreased
safety of the child and increased infantile colic. Pharmacists
have the ability to provide a crucial role in evaluating a patient’s depression, helping to select proper treatment, evaluating treatment progress and educating the patient. An interdisciplinary health care team can collaborate to help individualize the patient’s treatment with maximal benefit.
Overview of Depression: Pathology, Symptoms, Diagnosis and Treatment
Although the pathophysiology of depression is unclear, one
hypothesis points to a dysfunction in neurotransmitter signaling which includes the availability and concentration of
neurotransmitters, receptor activation and response in the
neuron.2 Neurotransmitter imbalance is commonly thought
to be the cause of depression. Neurotransmitters that are
affected include serotonin (5-HT), norepinephrine (NE),
dopamine (DA), glutamate and brain-derived neurotrophic
factor (BDNF). Depression is caused by a decreased concentration of these neurotransmitters, a lack of effective activation of their receptors or a combination of both.
The site of 5-HT synthesis in the brain is the dorsal raphe
nucleus where the reaction catalyzed by tryptophan hydroxylase is the rate-limiting step.3 Tryptophan hydroxylase is an
enzyme involved in the hydroxylation of the essential amino
acid L-tryptophan to form 5-hydroxytryptophan, which is the
precursor for 5-HT. The removal of 5-HT from the synapse is
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completed either through degradation by the enzyme monoamine oxidase (MAO) or its removal from the synapse
through the serotonin-reuptake transporter located on the
presynaptic neuron.2
The other significant neurotransmitters involved with the
pathology of depression are NE and DA. Both of these neurotransmitters are synthesized in the mesocortical and mesolimbic regions of the ventral tegmental area of the brain. The
rate-limiting step in the synthesis of both DA and NE is the
action of the tyrosine hydroxylase, which catalyzes the hydroxylation of the amino acid L-tyrosine to L-dihydroxyphenylalanine (L-DOPA), which is converted to DA and then
to NE. The removal of NE and DA is either accomplished by
MAO or catechol-o-methyltransferase (COMT) metabolism or
reuptake into the presynaptic cleft by either the norepinephrine reuptake transporter or the dopamine reuptake transporter, respectively.2 Because these medications work at the
receptor level, it takes time for the full effectiveness of the
medication to be seen. It takes about two weeks for most
antidepressants to start to relieve some depression symptoms, and it takes about six to eight weeks to reach its full
effect from the initiation of therapy.4
The signs and symptoms of depression vary in degree from
patient to patient. In pregnant patients, the onset of depression can vary from the start of pregnancy to development
postpartum.5 Pregnancy is associated with increased hormone levels; it was found that pregnant patients have 30
times higher estrogen levels compared to women who are
not pregnant. Pregnant patients also have increased cortisol
levels comparable to those in patients with major depressive
disorders. The associated symptoms of depression in
pregnancy found in a study by Castro and colleagues include
depressed mood, feeling worse in the morning, decreased
energy, lack of concentration, sensitivity to criticism and feelings of heavy limbs. The authors noted these symptoms were
experienced to a higher degree at the beginning and end of
pregnancy than in the middle.
The diagnosis of depression is based on the fifth edition of
the Diagnostic and Statistical Manual of Mental Disorders
(DSM-V) criteria.6 A patient is diagnosed with depression if
the patient exhibits symptoms of depressed mood or anhedonia, along with at least four other symptoms.7 These other
symptoms include the following: change in weight or appetite, insomnia, fatigue, feelings of worthlessness or inappropriate guilt, indecisiveness, recurrent thoughts of death or
recurrent suicidal ideation, and psychomotor agitation or
retardation. These symptoms must be present nearly every
day during the same two week period and must represent a
change from the patient’s previous functioning.
Several different depression rating scales can be used to
evaluate if a person has depression as well as to monitor the
patient’s progress throughout treatment. A few common
scales include the Hamilton Rating Scale for Depression
(HAM-D), Structured Clinical Interview mood module for
depression and the Clinical Global Impressions Scale.7 The
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HAM-D is commonly seen in drug studies and is considered
the standard for comparison of other depression rating
scales. The HAM-D is used for screening, determination of
disease severity and assessment of outcomes. It is important
to note that none of these scales are specific for evaluating
depression in pregnant women.
In general, pharmacologic treatment of depression includes
the first generation antidepressants (tricyclic antidepressants (TCAs) and MAO inhibitors) and the second generation
antidepressants which include the newer, more favorable
treatment classes (serotonin reuptake inhibitors (SSRIs) and
serotonin and norepinephrine reuptake inhibitors (SNRIs)).8
Many health care professionals are reluctant to use these
drugs during pregnancy, leading to the undertreatment of
this disease in pregnant women. The appropriate use of
pharmacologic medications in pregnancy to treat depression
as well as nonpharmacologic treatment of depression will be
further elaborated on in this article.
Epidemiology and the Impact of Depression in Pregnancy
The incidence of depression in pregnant women varies according to many contributing factors.9 These factors include
the age of the mother, whether the pregnancy was intended
or unintended, marital status, socioeconomic status, history
of domestic violence and comorbid diseases. It is estimated
that 10 percent of pregnant mothers deal with depression,
either as a result of the pregnancy or a relapse of pre-existing
depression during pregnancy. Depression that is diagnosed
before pregnancy must still be monitored prior to and after
conception for the optimization of outcomes for both mother
and child. Depression during pregnancy is characterized by a
relatively high frequency of somatic symptoms, which can
present as a lack of energy or suicidal thoughts. Consequences of depression in pregnancy include medical complications
such as preeclampsia, inadequate prenatal care such as an
imbalanced diet or use of tobacco, alcohol or illicit drugs.
Depression during pregnancy can cause stress on the mother
which has been linked to preterm birth.10 Smith and colleagues completed a study of 4,672 women from 2009 to
2011 to investigate the rate of depression in pregnancy. A
total of 4,123 women were evaluated after excluding those
with unknown marital status, unknown smoking status, unknown use or use of alcohol, those who developed gestational diabetes and women under 18 years of age or over 40
years of age. Of the 4,123 women, 8.05 percent (n=4,123)
were told that they had depression at some point during
their pregnancy. Compared to women who were not told
they had depression while pregnant, those who were told
they had depression while pregnant had statistically significantly increased odds of preterm birth with the reported
odds ratio (OR) of 1.51 at a 95 percent confidence interval
(CI) of 1.07 to 2.12. When adjusted for appropriate number
of prenatal visits, the OR dropped to 1.29 and was no longer
statistically significant (95 percent CI 0.9, 1.85). The selfreporting of depression in this study and the observational
design limit the interpretation of this data.
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Management of Depression During Pregnancy
Major depressive disorder in pregnancy is diagnosed using
DSM-V guidelines.6 The DSM-V guidelines define major
depressive disorder with postpartum onset as a major depressive episode with onset within four weeks of delivery. 7
According to the major depressive disorder guidelines, prescribers should always evaluate the risks and benefits of
pharmacotherapy during pregnancy and breastfeeding including the risks of untreated mood disorder and the lack of
knowledge regarding the safety of drug therapy. Dose requirements may change during pregnancy due to changes in
volume of distribution, metabolism and gastrointestinal absorption. While there is little controlled, long-term research,
psychotherapies appear to be efficacious for depression during pregnancy and postpartum depression. The American
Psychiatric Association and American College of Obstetricians and Gynecologists recommend psychotherapy as the
first-line option for those who are not currently prescribed
an antidepressant.11
Nonpharmacologic Treatment
Nonpharmacologic options are abundant for treating depression and are first-line options for women who are pregnant.
One of these first-line nonpharmacologic options is interpersonal therapy (IPT) which may be useful for women who
have never been prescribed an antidepressant.12 If medication therapy must be considered, the patient should still continue the psychotherapy throughout the treatment process.
Other nonpharmacologic options include peer or partner
support, massage therapy, bright light therapy, acupuncture,
nutrition, weight management, childbirth education and prenatal care.
Manber and colleagues conducted a study in which a total of
150 pregnant women who met the criteria for major depressive disorder were randomized to either treatment with
acupuncture specific for depression or one of two active controls: control acupuncture or massage.13 The junior acupuncturists were blinded, and treatments lasted eight weeks. The
primary outcome of this study was the HAM-D score administered by the acupuncturists at baseline and after four and
eight weeks of treatment. Women who received acupuncture
specific for depression had a greater decrease in symptoms
(p<0.05, CI 0.01-0.92) when compared to the controls. Those
receiving acupuncture also had a greater response rate
(defined as a 50 percent reduction in the HAM-D score from
baseline) compared to the combined controls (p<0.05,
CI 2.2-75.0). This study demonstrates that acupuncture may
be a viable treatment option for depression in pregnancy.
Pharmacologic Treatment
As stated, SSRIs are one of the favored drug classes for the
treatment of depression. The SSRIs work to improve serotonergic functioning by inhibiting the reuptake of serotonin
from the synapse through the reuptake transporters on the
presynaptic neuron.4 Examples of SSRIs include fluoxetine,
paroxetine, citalopram, escitalopram and sertraline. If a
pregnant patient fails therapy with nonpharmacologic options, an SSRI may be the next option that is considered. The

4

American Psychiatric Association guidelines for major depressive disorder do not specify one SSRI as being superior
to others for use during pregnancy, but there are some suggestions stated in the guidelines as shown in Table 1.7,14-17
Specific guidelines related to use of psychiatric medications
in the pregnant patient warn against the use of paroxetine
due to potential fetal harm.18 Health care providers must
assess the individual patient when beginning pharmacologic
therapy and weigh the benefits against the potential adverse
effects. In 2006, the U.S. Food and Drug Administration
(FDA) issued a warning that the use of SSRIs in pregnancy
has been associated with persistent pulmonary hypertension
of the newborn (PPHN). However, in 2011, the FDA stated
there was not enough evidence to link PPHN to SSRI use.19
There is concern that 30 percent of infants born to mothers
taking SSRIs in the third trimester have exhibited symptoms
of withdrawal including jitteriness, hypoglycemia, rapid
breathing, irritability, weak cry and seizures.
Depression has also been associated with an irregularity of
omega-3 polyunsaturated fatty acids.20 Therefore, it is hypothesized that taking omega-3 fatty acid supplements may
help relieve symptoms caused by low levels. In an eight
week, double-blind, placebo-controlled trial conducted in
pregnant women with major depressive disorder, Su and
colleagues evaluated the efficacy of omega-3 fatty acid supplementation as monotherapy in the treatment of depression during pregnancy in 24 pregnant women. As a measure
of efficacy, individual HAM-D scores were recorded every
other week. Response rate was characterized as a 50 percent
improvement in HAM-D score compared to baseline. Compared to the placebo group, those taking omega-3 supplements had significantly lower HAM-D scores at weeks six
and eight (p=0.001, 0.019, respectively), a higher response
rate (p=0.03) and, while not statistically significant (p=0.28),
a higher remission rate. In conclusion, omega-3 fatty acid
supplements may have benefits for treating depression during pregnancy, but evaluation may need to be repeated in
studies with a larger sample size.
Modification of Pharmacologic Therapy Prior to Conception
Women who have been diagnosed with depression prior to
conception must be evaluated by a psychiatrist before making changes to their medication.14 Women who are being
actively treated for depression and are trying to become
pregnant should consider speaking with their psychiatrist
about the continuation or discontinuation of their therapy
based on their depression management. The psychiatrist
must evaluate the patient’s risks, relapse history, suicide
history and severity of depression before considering discontinuation or decrease in dose of the medication prior to
pregnancy. If the patient has been symptom free for six
months or greater, tapering off the antidepressant prior to
conception may be a worthwhile consideration. However,
discontinuation may not be appropriate in those with a history of suicide attempts or episodes of psychosis.
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Table 1: A Review of Antidepressant Drugs for use in Pregnancy.7,14-16
Medication

FDA Pregnancy
Category*

Potential Adverse Event in Pregnancy and/or Breastfeeding

Selective Serotonin Reuptake Inhibitors (SSRIs)
Paroxetine

D

Cardiac malformations

Fluoxetine

C

Minor physical abnormalities, lower birth weight, lower maternal weight
gain, longer half-life than other SSRIs
Breastfeeding: decreased feeding, irritability, watery stools and crying

Sertraline

C

Lower cord blood levels, but unknown significance to the fetus

Citalopram

C

Breastfeeding: decreased feeding, irritability, watery stools and crying

Escitalopram

C

No confirmed evidence of birth defects when used in the first trimester;
risk of SSRI withdrawal syndrome when used in the third trimester
Tricyclic Antidepressants

Desipramine,
Imipramine,
Nortriptyline

Inconclusive
data

Congenital abnormalities have been reported in humans,
but a causal relationship has not been established.

Other Antidepressant Agents
Bupropion

C

The benefit for smoking cessation may make it preferred for
women who are pregnant with Major Depressive Disorder
and wish to quit smoking.

Venlafaxine

C

Limited data suggests there may be an increase in birth defects
and spontaneous abortion.

Duloxetine

C

In animal studies, nonteratogenic effects in the newborn following third
trimester exposure include respiratory distress, jitteriness, irritability,
crying and tremor.

Mirtazapine

C

Limited data available; no confirmed evidence of birth defects when used
in the first trimester.

* The use of the pregnancy category will be eliminated over the next few years per the U.S. Food and Drug Administration’s new labeling
requirements.17

Cohen and colleagues looked at relapse rates of depression
during pregnancy, comparing mothers who chose to stay on
their medication to mothers who chose to discontinue therapy.21 Of the 201 mothers included in the trial, 86 women experienced a relapse in depression during pregnancy. Of
mothers who continued their medication, only 26 percent
(n=21) relapsed. The mothers who discontinued their medication experienced a significantly higher rate of relapse, 67.7
percent (n=44, p<0.001). This study demonstrates that medication can help reduce the rate of relapse, but even pregnant
women who are being treated with medications are still at
risk for experiencing a relapse of their depression.

Exercise Benefits
Exercise is another type of therapy that can be used in place
of or in addition to pharmacologic agents for women who
have depression or who are at a greater risk of experiencing
depression during pregnancy. A study done by El-Rafie and
colleagues found that exercise during pregnancy reduced
depression symptoms.22 This study examined 100 different
females who completed the 20-item, Center for Epidemiologic Studies Depression Scale (CES-D). Aerobic exercise totaling
60 minutes a week was prescribed for 50 patients, while the
other 50 patients did not perform any exercise. There was no
significant difference in the CES-D score at baseline between
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the groups. The results showed a significant reduction of
depressive symptoms in the exercise group. After three
months, the mean CES-D score decreased from 20.2 to 14.8
in the exercise group while the mean CES-D score was 20 in
the control group at both baseline and three months
(p<0.001).
New patterns, such as a new exercise routine, that are embraced during pregnancy could potentially affect a woman’s
health throughout her lifespan.23 The American College of
Obstetricians and Gynecologists and the American College of
Sports Medicine recommend an accumulation of 30 minutes
or more of moderate intensity exercise preferably seven
days a week. An activity with an energy requirement of three
to five metabolic equivalents (METS) is considered moderate
activity. For example, a brisk walk at about three to four
miles per hour is considered moderate activity. There are
some contraindications to exercise for some pregnant women based on underlying conditions, so it is recommended
that women interested in pursuing exercise during pregnancy should talk with their physician first to establish a safe
exercise program.
Exercise for pregnant women should include aerobic exercise that uses large muscle groups in a continuous rhythmic
contraction.23 Activities such as walking, jogging, running,
dancing and swimming, which are easily monitored for intensity, would be useful. Before prescribing modes of exercise with excessive joint stress, women should be aware that
due to the increased weight gain during pregnancy, they will
experience an increase in forces at the joints during weight
bearing exercise, including more joint discomfort. The prescriber should carefully balance weight bearing versus non
weight bearing activities. In addition to aerobic training, low
weight resistance training and flexibility exercises should be
incorporated into the exercise plan. Isometric or heavy resistance weight lifting should be completely avoided during
pregnancy as such activities may result in vasoconstrictive
effects.
If the pregnant woman has not engaged in physical activity
before, the proper exercise intensity should be at about 50 to
60 percent of the woman’s maximum oxygen uptake.23
Women who were active before pregnancy may exercise at
60 to 85 percent of their maximum oxygen uptake. An easier
way to track exercise intensity is to use ratings of perceived
exertion on the six to 20 scale. A score of 12 to 14 is considered to be moderate intensity exercise.
Women participating in any type of exercise need to review
proper hydration and nutrition.23 Pregnant women have an
average core body temperature that is 1.5 degrees Celsius
warmer than that of nonpregnant women. Because of this
increase in temperature, pregnant women will sweat more
during exercise and will need to drink more water than they
were used to drinking before pregnancy. In addition to
drinking more water, pregnant women should exercise in a
controlled environment with air conditioning. Following the
above suggestions with physician approval, pregnant women
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with an increased likelihood of having depression during
pregnancy can participate in moderate intensity exercise.
Risks Associated With Untreated Depression During
Pregnancy
It is known that evaluating the risks versus the benefits of
pharmacologic treatment of depression during pregnancy is
imperative. However, there are also health risks if the patient refuses pharmacologic treatment and is unstable with
psychotherapy alone. Left untreated, depression during
pregnancy is one of the greatest risk factors for developing
postpartum depression.14 Associated outcomes with unmanaged depression postpartum include increased rates of maternal suicide as well as infanticide. Mothers experiencing
postpartum depression have been associated with harsher
parenting behavior compared to those not experiencing
postpartum depression, resulting in decreased safety and
development of the child. Additionally, higher rates of infantile colic have been noted in this population as well as decreased mother-infant bonding.
Identification and Management of Postpartum Depression
Identification
Prenatal focus on psychological well-being may help to identify women at risk of postpartum depression. Forman and
colleagues conducted a prospective follow-up study based
on questionnaires at an antenatal care clinic and delivery
ward at Aarhus University Hospital located in Denmark.24
The researchers evaluated psychiatric disease, distress and
social support during pregnancy as well as four months
postpartum using the Edinburgh Postnatal Depression Scale.
Forman and colleagues enrolled 5,091 women giving birth
between January 1994 and December 1995 who completed
the questionnaires. It was found that 5.5 percent (n=281) of
these women were suffering from postpartum depression
(defined as a score of 13 or higher on the Edinburgh Postnatal Depression Scale). In a multivariate regression analysis,
the researchers determined several risk factors were highly
linked to postpartum depression. The greatest association of
risk for postpartum depression was psychological distress in
late pregnancy with an OR of 6.3 (95 percent CI 4.4-9.1)),
followed by social isolation during pregnancy (OR 3.6 (95
percent CI 1.9-7.01)) and a positive history of prepregnant
psychiatric disease (OR 2.1 (95 percent CI 1.4-3.21)). The
authors estimated one out of three women with both psychological distress and social isolation late in pregnancy will
develop postpartum depression. Complications during pregnancy and delivery were not associated with development of
postpartum depression. This study shows the importance of
focusing on women during their pregnancy to help identify
those at risk of developing postpartum depression.
Management
Nonpharmacologic options have also been found to help
treat postpartum depression. Psychotherapy is recommended as first-line treatment for patients with mild to moderate
depression and no previous history of depression.19 O’Hara
and colleagues looked specifically at IPT as a way to treat
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postpartum depression.25 A total of 99 postpartum women
with major depression were assigned to either receive IPT or
were put on a waiting list. Interpersonal psychotherapy was
administered in 12 one hour long individual sessions during
a 12 week period. Self-reports, such as HAM-D, were given
every four weeks to evaluate depressive symptoms and social adjustments. The HAM-D scores in those receiving IPT
dropped from 19.4 to 8.3, which was significantly greater
than those in the waiting list group in which patients’ scores
declined from 19.8 to 16.8 (p=0.003). Furthermore, O’Hara
and colleagues noted the patients’ Beck Depression Inventory Score (BDI). The BDI score for women receiving IPT declined from 23.6 to 10.6 over 12 weeks, which was another
significant difference from the waiting list group whose
scores went from 23.0 to 19.2 (p<0.001). Women receiving
IPT also had a significant improvement on the Postpartum
Adjustment Questionnaire and the Social Adjustment Scale
(p<0.001). These results suggest that IPT is as efficacious in
the treatment of postpartum depression as it is for depression during pregnancy.
Exercise Benefits
Some women may use exercise as a nonpharmacologic treatment for postpartum depression. In a study conducted by
Songoygard and colleagues, it was found that women who
were not physically active before pregnancy, but exercised
during pregnancy, had a lower rate of postpartum depression.26 According to the Guidelines by the American College
of Obstetricians and Gynecologists, women who delivered
without complication should resume their exercise gradually
and with approval of a physician.23 The exercise program
should be individualized and light intensity at first. Some
women can start light intensity exercise days after delivery;
however, that is not the case for all mothers. Many morphological and physiological changes are still occurring in a
woman’s body four to six weeks after delivery, and exercise
may not be recommended for some women until after this
time. While exercise can be beneficial for women, women
should always consult their physicians to make sure exercise
is safe to resume postpartum.
Pharmacologic Considerations
Antidepressants are indicated for patients with moderate to
severe postpartum depression or if they have responded to
antidepressant therapy in the past.19 The major concern with
initiation of antidepressant therapy is the question of safety
with breastfeeding. The U.S. National Library of Medicine
maintains a database on the effects of drugs and chemicals
on breastfed infants called LactMed. LactMed is a subset of
the toxicology data network TOXNET.27 A summary of the
recommendations from this group with regard to the safety
of antidepressant use during breastfeeding is shown in Table
2. A number of authoritative reviews have been written on
this subject and all suggest mothers should continue to
breastfeed if antidepressant therapy is initiated.28-33 Sertraline or paroxetine should be suggested to mothers first, as
these two medications are shown to be excreted in breast
milk in negligible amounts and have not been detected in
serum of the infant. Although there is some concern shown in

Drug Abuse
Women’s
Health

those taking fluoxetine, citalopram or venlafaxine, due to low
levels detected in breast milk, it should not be advised to
switch to a “safer” alternative if the mother has been treated
with one of these medications previously. In all cases, if an
antidepressant is initiated in a mother who is breastfeeding,
the infant should be monitored closely for excessive sedation, irritability, poor feeding or poor weight gain.34
The Role of Health Care Professionals in Depression Education and Management
The American Psychiatric Association’s Committee on Research on Psychiatric Treatments has identified the treatment of major depression during pregnancy as a leading area
for improvement in clinical management which should be a
priority.34 A model was created to give psychiatrists power to
structure the problem through diagnostics and identification
of treatment options for depression. Reproductive toxicity,
the depression itself and how it could compromise health
during pregnancy, the patient’s willingness to participate and
treatment outcomes should all be considered. The patient’s
loved ones, obstetrical physician and other health care professionals such as doctors and pharmacists should be involved in this ongoing process, as treatment response and
progress should also be monitored. By applying this model, it
ensures that clinicians look at critical aspects of the risks and
benefits and include those considerations in their care of
pregnant women with depression.
Pharmacist’s Role
As part of an interdisciplinary team, pharmacists, along with
other health care professionals, must use a collaborative approach to optimize the treatment outcomes for the patient;
steps for appropriate collaborative treatment include the
following:14
1. Individualize the treatment based on the mother’s
illness.
2. Educate the mother on the risks and benefits of
pharmacologic treatment compared to nonpharmacologic treatment.
3. Provide firm clarity in recommendations, being careful not to send “mixed-signals” to the mother.
4. Implement a universal screening method when evaluating the mother.
5. Eliminate the stigma that is associated with depression and minimize the fears of the unknown by educating the mother on the dynamics of the disease.
6. Prioritize the mental and physical health of the
mother and baby.
It is imperative that patients receive medication counseling
from a pharmacist to achieve the best outcomes for their depression. A pharmacist can help patients manage depression
during pregnancy through education, monitoring and assistance with adherence. It is important to support the mother’s
treatment decisions, whether she chooses pharmacologic or
nonpharmacologic treatment. Pharmacists can monitor patients by asking the mother how she is doing on the medication, how she is feeling in regard to mood control, what signs
and symptoms of depression she feels need addressed and if
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Table 2. Safety of Antidepressant Medications During Breastfeeding.27
Drug

Concerns

Recommendation
Selective Serotonin Reuptake Inhibitors (SSRI)

8

Sertraline

Negligible levels of sertraline found in
breastmilk , but low levels detected of
active metabolite;
In preterm infants, potential for accumulation of drug and possible neonatal abstinence symptoms;
Potential to impair lactation (class effect)

Considered one of the preferred antidepressants during
breastfeeding

Paroxetine

Negligible levels of paroxetine found in
breastmilk.
Symptoms consistent with neonatal
abstinence have been reported such as
insomnia, restlessness and increased
crying.
Potential to impair lactation (class effect)

Considered one of the preferred antidepressants during
breastfeeding

Fluvoxamine

Low levels detected in breastmilk,
although not expected to cause adverse
effects.
Potential to impair lactation (class effect)

No adverse effects have been reported; can be considered an option

Fluoxetine

Compared to other SSRIs, has higher
average amount of drug and active metabolite detectable in breast milk; Serum
levels of the metabolite are detectable in
infants less than 2 months of age;
Some reports of adverse effects including
increased crying, irritability, decreased
sleep, reduced growth.
Potential to impair lactation (class effect)

Not considered first choice in lactating women; can be
used in conjunction with breastfeeding if mother was
maintained effectively on this during pregnancy, or if
other options are ineffective in managing the depression.

Citalopram

Levels detected in breastmilk and in
serum of infants.
Reports of minor behavioral side effects
such as drowsiness and fussiness; no
adverse effects on development noted in
one year follow-up.
Potential to impair lactation (class effect)

Not considered first choice in lactating women; can be
used in conjunction with breastfeeding if mother was
maintained effectively on this during pregnancy, or if
other options are ineffective in managing the depression.

Escitalopram

Levels detected in breastmilk and in
serum of infants.
One report of necrotizing enterocolits in
breastfed newborn whose mother was
treated with escitalopram, although
causality not confirmed.
Potential to impair lactation (class effect)

Lower levels detected in breastmilk as compared to
citalopram so may be preferable choice between these
two agents.
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Table 2 (continued). Safety of Antidepressant Medications During Breastfeeding.27
Drug

Concerns

Recommendation
Serotonin Norepinephrine Reuptake Inhibitors (SNRI)

Venlafaxine

Desvenlafaxine

Levels of venlafaxine and its metabolite
desvenlafaxine are noted in breastmilk
and in plasma of breastfed infants.
Potential to impair lactation (class effect)

Levels of desvenlafaxine are detected in
breastmilk and in plasma of breastfed
infants, although total drug exposure is
about half of that noted with venlafaxine.
Potential to impair lactation (class effect)

Not considered first choice in lactating women due to
higher levels noted in breastmilk and infant’s serum; can
be used in conjunction with breastfeeding if mother was
maintained effectively on this during pregnancy, or if
other options are ineffective in managing the depression.
No adverse effects in infants reported, but infants should
be monitored closely due to potential drug exposure.

Not considered first choice, but may be preferable to
venlafaxine if an SNRI is desired.
No adverse effects in infants reported, but infants should
be monitored closely due to potential drug exposure.

Tricyclic Antidepressants (TCA)
Nortriptyline

Low levels detected in breastmilk, generally not detected in serum of the infant.

Considered one of the preferred antidepressants during
breastfeeding if appropriate for the mother.
No adverse effects in infants reported.

Imipramine

Low levels detected in breastmilk, generally not detected in serum of the infant.

Considered one of the preferred antidepressants during
breastfeeding if appropriate for the mother.
No adverse effects in infants reported.

Desipramine

Low levels detected in breastmilk, generally not detected in serum of the infant.

Not expected to cause any adverse effects although
limited information available.

Miscellaneous

Bupropion

Low levels detected in breastmilk and
minimal serum levels noted in infants.
Two case reports of infant seizures
possibly related to bupropion; In both
cases, infants were exposed after six
months of age.

Not considered first choice in lactating women; can be
used in conjunction with breastfeeding if mother was
maintained effectively on this during pregnancy, or if
other options are ineffective in managing the depression.

Maprotiline

Low levels detected in breastmilk; no
information on serum levels in infants.

No reports of adverse effects, although information is
very limited to make a strong recommendation for safe
use.

Duloxetine

Low levels detected in breastmilk; no
reports of measureable serum levels in
infants.
Potential to impair lactation (class effect)

No reports of adverse effects, although information is
very limited to make a strong recommendation for safe
use.

Mirtazapine

Low levels detected in breastmilk; negligible levels detected in serum of infants.
Unclear if any effects on lactation.

No reports of adverse effects, although information is
very limited to make a strong recommendation for safe
use.
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she has any questions about her medication and pregnancy.
A pharmacist can counsel on both antidepressant use during
pregnancy as well as the effects of untreated depression during pregnancy to help the mother make the most informed
choice of whether to continue or discontinue her chosen
therapy. The pharmacist can also review the diagnosis and
severity of depression and help to identify any comorbidities
that may complicate treatment.
Pharmacists can continue to help to manage depression during the postpartum period. For example, a pharmacist can
explain the benefits that breastfeeding has to the newborn
and any associated risks with medications and breastfeeding. The pharmacist can help the mother make the most informed decision about whether to continue therapy and
breastfeed, continue therapy and bottle feed or postpone
therapy to breastfeed based on the risks versus benefits of
the medication.
Follow-up with the patient is another key aspect of care in
which pharmacists can participate. Pharmacists can follow
up with the patient via outreach phone calls and counseling
appointments to ensure that the patient is benefitting from
the therapy. The pharmacist should emphasize the importance of adherence to antidepressant medications, as it
takes time for some antidepressants to take full effect. The
pharmacist should discuss side effects and best practices for
taking the medications for the best chance for improvement.
Exercise Physiologist’s Role
In order for prescribed exercise treatment to work well, it is
crucial to have the patient follow up consistently with an
exercise physiologist.23 The exercise physiologist will monitor well-being and any complications and report them back
to the physician and pharmacist. An integrated system between physician, pharmacist and exercise physiologist is
needed to assure the patient's depression is treated properly. The exercise physiologist will make any changes deemed
necessary or beneficial to the patient after careful discussion
with the pharmacist and physician.
Conclusion
With more evidence of depression in pregnancy and postpartum depression getting more attention in the media, it is
becoming critical that health care professionals are aware of
related treatment considerations, risks, benefits and potential side effects. In addition, an interdisciplinary team of
health care providers is instrumental in helping patients
treat and manage depression prior to, during and after pregnancy. Health care professionals can be prepared to answer
patient questions, give advice and collectively formulate an
individualized treatment plan for the patient. Health care
providers should be aware of risk factors for depression as
well as the many options that can be used to treat depression in pregnancy. Providing both pharmacologic and nonpharmacologic therapies to treat expectant mothers and
women postpartum with a diagnosis of depression will benefit not only the new mother but also the health of the infant.
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Assessment Questions
1.

Which of the following is not a typical symptom of
depression in pregnancy?
A. Decreased energy
B. Lack of concentration
C. Sensitivity to criticism
D. Feeling worse in the evening

2.

DSM-V criteria for depression includes all of the following EXCEPT:
A. Depressed mood or anhedonia
B. Weight and appetite changes
C. Insomnia, fatigue, feelings of worthlessness
D. Metabolic changes such as dyslipidemia

3.

The first-line treatment option for treating a new onset
of depression during pregnancy is:
A. SSRI
B. Nonpharmacologic therapy
C. SNRI
D. TCA

4.

Which of the following SSRIs is not correctly paired with
its associated adverse event profile?
A. Paroxetine: fetal cardiac malformations
B. Citalopram: spontaneous abortions
C. Escitalopram: risk of withdrawal symptoms
when used during the third trimester
D. Nortriptyline: congenital abnormalities

5.

6.

12

It takes about ______ for most antidepressants to start to
relieve some depression symptoms, and it takes about
_______ to reach the full antidepressive effect.
A. 1 week, 4 weeks
B. 2 weeks, 4 weeks
C. 2 weeks, 6-8 weeks
D. 4 weeks, 6-8 weeks

Which is not a role of the pharmacist in the treatment of
depression during pregnancy?
A. Explain the benefits of breastfeeding and its
associated risk
B. Help the mother make an informed decision
about continuing therapy
C. Follow up with the patient, emphasizing the importance of medication adherence
D. Choose a treatment option for her, without her
input

7.

What is the type of exercise recommended in the
treatment of depression during pregnancy?
A. Anaerobic, high velocity, continuous
contractions involving small muscle groups
B. Anaerobic, low velocity, continuous contractions
involving large muscle groups
C. Aerobic, continuous, rhythmic contractions
involving large muscle groups
D. Aerobic, noncontinuous, rhythmic contractions
involving large muscle groups

8.

All of the following are appropriate approaches for depression management in a female patient with depression who is trying to conceive EXCEPT:
A. Immediately discontinue the use of antidepressant medications before conception
B. Consider decreasing the dose of antidepressants
if depression is controlled prior to conception
C. Consider discontinuing the antidepressant by
tapering down if depression is controlled prior
to conception
D. Consider switching the patient to the safest
antidepressant drug therapy if not currently
prescribed

9.

If deemed an appropriate option for treatment, what is a
viable first-line nonpharmacologic option for depression
during pregnancy?
A. Interpersonal therapy (IPT)
B. Massage therapy
C. Yoga
D. Meditation

10. Which antidepressant has been shown to be excreted in
breast milk in an amount undetectable in an infant?
A. Venlafaxine
B. Sertraline
C. Citalopram
D. Fluoxetine
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